Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 1, 1988
[Phase III study of carboplatin in ovarian cancer]T Kato, H Nishimura, T Yamabe, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 1, 1992
[Phase III study of DWA2114R for ovarian cancer]T Kato, M Yakushiji, H Nishimura, et al.
Japanese Journal of Cancer Research : Gann|September 1, 1992
Maternal transmission of HTLV-1 other than through breast milk: discrepancy between the polymerase chain reaction positivity of cord blood samples for HTLV-1 and the subsequent seropositivity of individualsK Kawase, S Katamine, R Moriuchi, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 1, 1994
[Long-term administration of carmofur as a post-operative adjuvant chemotherapy for cervical adenocarcinoma. Cervical Adenocarcinoma Cooperative Research Association]M Ikeda, K Teshima, K Noda, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 1, 1988
[Phase II study of carboplatin in ovarian cancer]T Kato, H Nishimura, T Yamabe, et al.
The Journal of Clinical Investigation|June 1, 1995
Association between maternal antibodies to the external envelope glycoprotein and vertical transmission of human T-lymphotropic virus type I. Maternal anti-env antibodies correlate with protection in non-breast-fed childrenS Hino, S Katamine, T Miyamoto, et al.
Journal of Neuroimmunology|January 1, 1994
Cytokine-gene expression in measles-infected adult human glial cellsT Yamabe, G Dhir, E P Cowan, et al.
Journal of Thrombosis and Haemostasis : JTH|September 27, 2015
Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trialG Agnelli, H R Buller, A Cohen, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 9, 1999
[Late phase II trial of oral etoposide administered for 21 consecutive days in patients with cervical cancer. ETP 21 Study Group--Cervical Cancer Group]M Ikeda, K Noda, M Hiura, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|December 5, 1998
[Early phase II trial of oral etoposide administered for 21 consecutive days in patients with cervical or ovarian cancer. ETP 21 Study Group--Cervical-Ovarian Cancer Group]K Noda, K Tanaka, M Ozaki, et al.
Pageof 8